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Correlation between serum and synovial fluid estrogen
concentrations: comment on the article by Sowers
et al
To the Editor:
There is already substantial evidence for a role of
estrogen in cartilage homeostasis (1), and the recent interest-
ing report by Sowers and colleagues (2) adds further support
for the existence of a link between estrogen deprivation and
osteoarthritis (OA). Sowers et al observed that low serum
estradiol (E2) concentrations in women were associated with
an increased risk of knee OA.
Nevertheless, the mechanisms by which serum estro-
gen levels could influence cartilage homeostasis are still un-
clear. One of the important remaining questions is whether
synovial fluid (SF) levels of estrogen parallel serum levels,
because the potential effects of estrogen on avascular cartilage
should be influenced mainly by local concentrations of the
hormone.
To answer this question, we evaluated the estrogen
concentrations in paired SF and serum samples from 21
premenopausal or postmenopausal women with knee OA. SF
was obtained from the knee during therapeutic arthrocentesis
and was stored at 80°C until analyzed. Joint fluid samples
were melted on ice and centrifuged at 10,000g for 15 minutes
to remove cellular debris. Total E2 concentrations in SF and
serum were determined by radioimmunoassay.
The mean  SD age of patients was 59  11 years. E2
concentrations in serum and SF were above the detection limit
(10 pg/ml) in 14 of 21 patients. In these patients, the mean 
SD serum and SF E2 concentrations were 38.25  9.74 pg/ml
and 18.83  5.70 pg/ml, respectively. There was a high and
positive correlation between serum and SF estrogen concen-
trations (r  0.93, P  0.0001). Age of patients was negatively
correlated with serum (r  0.79, P  0.0003) and SF E2 levels
(r  0.62, P  0.03).
These results show that estradiol is present in human
SF from OA joints, at concentrations closely reflecting serum
levels. The increased incidence of OA in postmenopausal
women might thus be explained by a decrease in local estrogen
concentrations, because E2 has been shown to have antidegra-
dative properties at physiologic levels (3–5).
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We thank Dr. Richette et al for their comments
supporting our rationale for extending evaluation of the role of
sex hormones and their metabolites in the development of OA.
In our study, we assayed circulating serum estradiol concen-
trations to characterize the sex hormone status of individual
women. Previously, it had been shown that estrogen receptors
were present in joint tissues, including bone and cartilage
(1–3), and we assayed serum under the assumption that the
systemic estradiol levels reflected the local joint environment.
Now, the data provided by Dr. Richette link the circulating
serum estradiol concentrations with parallel values in the local
synovial fluid environment.
These studies still do not identify what tissue (synovio-
cytes, chondrocytes, or bone cells) might be directly impacted
by the lower levels of estradiol or 2-hydroxyestrone, but these
new data do justify the assumption that circulating hormones,
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measured in a more accessible compartment, are a compatible
surrogate for the hormonal environment of the knee joint.
This new information also does not yet establish
whether our observed associations represent the response to a
receptor-mediated process (as in the case of lower estradiol
concentrations) or a cytokine-based response (as in the lower
urinary 2-hydroxyestrone concentrations), or potentially, both
mechanisms. There is little evidence that 2-hydroxyestrogens
have binding affinity to the estrogen receptor (4,5), but they
appear to have additional important properties, including
participation in oxidation/reduction actions (6), and may mod-
ulate arachidonic acid metabolism and the cyclooxygenase 1
(COX-1) and COX-2 enzymes.
MaryFran R. Sowers, PhD
University of Michigan
Ann Arbor, MI
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Are the ClASsification criteria for Psoriatic ARthritis
better than existing criteria for diagnosing psoriatic
arthritis? Comment on the article by Taylor et al
To the Editor:
We would like to congratulate Taylor et al for their
proposed classification criteria for psoriatic arthritis (PsA), the
CASPAR criteria (ClASsification criteria for Psoriatic ARthri-
tis), which were devised based on a study of a large cohort of
patients from several countries (1). We also appreciate the role
of the authors in modifying our group’s concept of PsA
pathology (2) for the purposes of disease classification, where
it fares rather well. Although the modified version of our
group’s criteria had the highest sensitivity of all diagnostic
criteria, it appeared to have low specificity in the CASPAR
study. We would like to point out the relevance of this for
clinical practice and especially for the early diagnosis of
disease, which does not come across in Taylor and colleagues’
report.
The major argument proposed in favor of the CAS-
PAR criteria, as acknowledged by Taylor et al, is that this
criteria set should be very useful for recruitment of patients
into clinical trials. However, the vast majority of patients with
PsA never participate in a clinical trial, and rheumatologists
more commonly struggle to determine whether a patient with
early inflammatory arthritis in fact has PsA. The specificity of
the CASPAR criteria relies in part on radiographic changes
that are a feature of late disease—hence their value for
classification and trial recruitment. Unfortunately, bone
changes, including spinal fusion and joint osteolysis, are irre-
versible at this stage. However, such radiographic features are
generally absent at the time of clinical presentation early in the
disease course (3). The criteria for PsA developed at our
institution were based on events that take place in early PsA,
when radiographic findings are usually normal (2). Therefore,
our group’s criteria may appear to have lower specificity than
the proposed CASPAR criteria, but they are principally aimed
at diagnosis of early disease, when magnetic resonance imaging
(MRI) or ultrasonography could be useful.
While it is not yet economically feasible to use MRI to
aid diagnosis, and the limitations of MRI for diagnosis of
enthesitis in synovial joints have not been resolved, we believe
the fact that our criteria demonstrated the highest sensitivity
compared with the other criteria sets suggests that they are
especially useful in the clinical setting for recognition and
diagnosis of early PsA; that is, oligoarthritis, spinal disease,
distal interphalangeal joint disease, and bone-based patholo-
gies including sacroiliitis all point toward PsA in a patient with
either current or past psoriasis or a strong family history of
psoriasis. Furthermore, the presence of any of the above
enthesitis/osteitis-related features in a patient with small joint
polyarthropathy is also suggestive of PsA. This classification
also allows one to conceptualize the coexistence of rheumatoid
arthritis, a disease related to autoimmune mechanisms
whereby the synovium is targeted, and PsA, a disease with a
different immunologic basis and a different primary anatomic
epicenter of disease. Therefore, our group’s criteria may be
usefulduringearlydisease inpatientswithsmall jointpolyarthro-
pathy without other enthesitis/osteitis-related features, in
whom MRI changes, including diffuse bone edema or extra-
capsular enhancement, would support the diagnosis of PsA
(4,5).
Like the CASPAR criteria, our group’s modified cri-
teria do not rely on the presence of current psoriasis to aid
diagnosis, but have the added advantage of allowing the
classification of rarer features of PsA, including the SAPHO
syndrome (synovitis, acne, pustulosis, hyperostosis, and oste-
itis). It is clear that as therapies become more targeted and
progressively move away from nonspecific immunomodula-
tion, early accurate diagnosis could become increasingly im-
portant (6). For rheumatologists the greatest challenge with
PsA remains its early recognition, especially in poor-prognosis
groups. What is remarkably clear from the CASPAR analysis is
that all of the criteria sets selected for study do indeed perform
very well for the purpose of classification. Perhaps the greatest
utility of the CASPAR classification criteria is that they clearly
demonstrate that North American and European rheumatolo-
gists view PsA from a very similar perspective and that this
international collaboration is contributing to significant ad-
vances in the clinical management of the disease.
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